Fundamental Analysis of THESEUS PHARMACEUTICALS INC(NASDAQ:THRX) stock

Fundamental Rating

Taking everything into account, THRX scores 3 out of 10 in our fundamental rating. THRX was compared to 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for THRX as it has an excellent financial health rating, but there are worries on the profitability. THRX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year THRX has reported negative net income.

THRX had a negative operating cash flow in the past year.

1.2 Ratios

With a decent Return On Assets value of -24.13%, THRX is doing good in the industry, outperforming 60.70% of the companies in the same industry.

The Return On Equity of THRX (-25.22%) is better than 70.65% of its industry peers.

		Industry Rank	Sector Rank
ROA	-24.13%
ROE	-25.22%
ROIC	N/A

ROA(3y)-57.73%

ROA(5y)N/A

ROE(3y)-68.96%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

THRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, THRX has about the same amount of shares outstanding.

THRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 9.94 indicates that THRX is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 9.94, THRX belongs to the top of the industry, outperforming 85.57% of the companies in the same industry.

THRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	9.94

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 29.94 indicates that THRX has no problem at all paying its short term obligations.

THRX has a Current ratio of 29.94. This is amongst the best in the industry. THRX outperforms 97.51% of its industry peers.

A Quick Ratio of 29.94 indicates that THRX has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 29.94, THRX belongs to the best of the industry, outperforming 98.01% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	29.94
Quick Ratio	29.94

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

THRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.61%.

EPS 1Y (TTM)-12.61%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%18.42%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.83% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-0.43%

EPS Next 2Y12.36%

EPS Next 3Y13%

EPS Next 5Y16.83%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

THRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year THRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

THRX's earnings are expected to grow with 13.00% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.36%

EPS Next 3Y13%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

THRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THESEUS PHARMACEUTICALS INC

NASDAQ:THRX (2/13/2024, 8:11:21 PM)

After market: 4.08 +0.02 (+0.49%)

4.06

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-17 2023-11-17/amc

Earnings (Next)03-07 2024-03-07/amc

Inst Owners0.03%

Inst Owner Change0%

Ins Owners13.19%

Ins Owner Change0%

Market Cap181.28M

Analysts77.78

Price Target5.36 (32.02%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)11.53%

Min EPS beat(2)7.48%

Max EPS beat(2)15.58%

EPS beat(4)4

Avg EPS beat(4)16.53%

Min EPS beat(4)7.48%

Max EPS beat(4)22.6%

EPS beat(8)6

Avg EPS beat(8)6.59%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-21.64%

EPS NQ rev (1m)0%

EPS NQ rev (3m)19.44%

EPS NY rev (1m)0%

EPS NY rev (3m)10.91%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.81
P/tB	0.81
EV/EBITDA	N/A

EPS(TTM)-1.34

EYN/A

EPS(NY)-0.96

Fwd EYN/A

FCF(TTM)-1.11

FCFYN/A

OCF(TTM)-1.11

OCFYN/A

SpS0

BVpS5.03

TBVpS5.03

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.13%
ROE	-25.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-57.73%

ROA(5y)N/A

ROE(3y)-68.96%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	100%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	29.94
Quick Ratio	29.94
Altman-Z	9.94

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-12.61%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%18.42%

EPS Next Y-0.43%

EPS Next 2Y12.36%

EPS Next 3Y13%

EPS Next 5Y16.83%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-40.74%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-168.47%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-168.03%

OCF growth 3YN/A

OCF growth 5YN/A

THESEUS PHARMACEUTICALS INC (THRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens